amphotericin B oral
Selected indexed studies
- Design of amphotericin B oral formulation for antifungal therapy. (Drug Deliv, 2017) [PMID:28155335]
- Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application. (Drug Deliv, 2023) [PMID:36601799]
- Development and deployment of a solid oral amphotericin B dosage form to treat visceral leishmaniasis within a pediatric population. (PLoS Negl Trop Dis, 2024) [PMID:39325693]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Design of amphotericin B oral formulation for antifungal therapy. (2017) pubmed
- Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application. (2023) pubmed
- Development and deployment of a solid oral amphotericin B dosage form to treat visceral leishmaniasis within a pediatric population. (2024) pubmed
- The oral delivery of amphotericin B. (2013) pubmed
- Amphotericin B cochleates: a vehicle for oral delivery. (2004) pubmed
- Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis. (2019) pubmed
- Targeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis. (2025) pubmed
- The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. (2009) pubmed
- Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: author's response. (2023) pubmed
- Enabling Oral Amphotericin B Delivery by Merging the Benefits of Prodrug Approach and Nanocarrier-Mediated Drug Delivery. (2023) pubmed